We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA
News

Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA

Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA
News

Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Advanced Cell Technology, Inc. has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD).

As many as 10 million people in the United States have photoreceptor degenerative disease. The treatment for eye disease uses stem cells to re-create a type of cell in the retina that supports the photoreceptors needed for vision. These cells, called retinal pigment epithelium (RPE), are often the first to die off in SMD and AMD, which in turn leads to loss of vision.
Advertisement